

# Sung-Yun Pai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2470628/publications.pdf>

Version: 2024-02-01

124  
papers

9,394  
citations

46918

47  
h-index

39575

94  
g-index

133  
all docs

133  
docs citations

133  
times ranked

10472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29410.	0.8	1
2	Intestinal atresias and intestinal failure in patients with TTC7A mutations. <i>Journal of Pediatric Surgery Case Reports</i> , 2022, 80, 102247.	0.1	2
3	A Curative DNA Code for Hematopoietic Defects. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 647-665.	0.9	6
4	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	2.0	36
5	Hematopoietic Stem Cell Transplantation Is a Curative Therapy for Transferrin Receptor 1 (TFRC) Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 753-759.e2.	2.0	4
6	Post-Transcriptional Genetic Silencing of <i>BCL11A</i> to Treat Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2021, 384, 205-215.	13.9	250
7	Novel Compound Heterozygous Mutations in ZAP70 Leading to a SCID Phenotype with Normal Downstream In vitro Signaling. <i>Journal of Clinical Immunology</i> , 2021, 41, 470-472.	2.0	2
8	Ten Years of Newborn Screening for Severe Combined Immunodeficiency (SCID) in Massachusetts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2060-2067.e2.	2.0	20
9	Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 820-842.	0.9	100
10	Defining a new immune deficiency syndrome: MAN2B2-CDG. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1008-1011.	1.5	19
11	Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency. <i>Frontiers in Immunology</i> , 2020, 11, 574738.	2.2	10
12	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. <i>Blood</i> , 2020, 135, 2094-2105.	0.6	87
13	Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency. <i>Blood Advances</i> , 2020, 4, 2606-2610.	2.5	28
14	Gene therapy for X-linked severe combined immunodeficiency: Historical outcomes and current status. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 258-261.	1.5	19
15	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. <i>Frontiers in Immunology</i> , 2020, 11, 239.	2.2	57
16	Transplantation Outcomes for Children with Severe Combined Immune Deficiency (SCID) Have Improved over Time: A 36-Year Summary Report By the Primary Immune Deficiency Treatment Consortium (PIDTC). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S18-S19.	2.0	3
17	Third-Party Virus-Specific T-Cell Infusion for Treatment of Refractory Viral Infections: Interim Results from PBMTC SUP1701. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S89-S90.	2.0	1
18	Lentiviral gene therapy for X-linked chronic granulomatous disease. <i>Nature Medicine</i> , 2020, 26, 200-206.	15.2	175

#	ARTICLE	IF	CITATIONS
19	Pulmonary Complications in Patients with Primary Immunodeficiency Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S16-S17.	2.0	1
20	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. <i>Journal of Clinical Immunology</i> , 2019, 39, 653-667.	2.0	41
21	Vasculitis as a major morbidity factor in patients with hypomorphic RAG mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB116.	1.5	2
22	174.â€fVASCULITIS AS A MAJOR MORBIDITY FACTOR IN PATIENTS WITH HYPOMORPHIC RAG VARIANTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
23	Universal Newborn Screening for Severe Combined Immunodeficiency (SCID). <i>Frontiers in Pediatrics</i> , 2019, 7, 373.	0.9	82
24	Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1970-1985.e4.	2.0	64
25	T-cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 306-309.e2.	1.5	13
26	Treatment of primary immunodeficiency with allogeneic transplant and gene therapy. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 457-465.	0.9	22
27	Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 848-855.	2.0	67
28	Immune Reconstitution Therapy for Immunodeficiency. , 2019, , 1115-1128.e1.		0
29	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 405-407.	1.5	64
30	Outcome of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome. <i>Blood</i> , 2019, 134, 4629-4629.	0.6	17
31	Inducible Phase Separation of GSK3 <sup>Î±</sup> As a Mechanism for Asparaginase Resistance in Acute Leukemias. <i>Blood</i> , 2019, 134, 169-169.	0.6	0
32	Long-Term Treatment Outcome in IPEX Syndrome Patients: An International Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S86-S87.	2.0	0
33	Patients with CD3G mutations reveal a role for human CD3 <sup>Î³</sup> in Treg diversity and suppressive function. <i>Blood</i> , 2018, 131, 2335-2344.	0.6	51
34	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1036-1049.e5.	1.5	233
35	WASP-mediated regulation of anti-inflammatory macrophages is IL-10 dependent and is critical for intestinal homeostasis. <i>Nature Communications</i> , 2018, 9, 1779.	5.8	40
36	Resolution of CGD Related Colitis after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Granulomatous Diseaseâ€”Early Results From the 6903 Study of the Primary Immune Deficiency Treatment Consortium (PIDTC). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S80-S81.	2.0	2

#	ARTICLE	IF	CITATIONS
37	Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass. <i>Cell Stem Cell</i> , 2018, 23, 775-776.	5.2	1
38	T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. <i>Genome Medicine</i> , 2018, 10, 70.	3.6	28
39	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.	0.6	128
40	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. <i>Blood</i> , 2018, 131, 2967-2977.	0.6	37
41	Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1363-1365.e8.	1.5	28
42	Congenital Disorders of Lymphocyte Function. , 2018, , 710-723.e3.		2
43	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018, 132, 1438-1451.	0.6	78
44	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€”The Primary Immune Deficiency Treatment Consortium (PIDTC). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S133-S134.	2.0	4
45	Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. <i>Blood</i> , 2017, 129, 2928-2938.	0.6	31
46	Immune reconstitution and survival of 100 SCID patients postâ€”hematopoietic cell transplant: a PIDTC natural history study. <i>Blood</i> , 2017, 130, 2718-2727.	0.6	212
47	Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1701-1713.	2.0	32
48	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. <i>Frontiers in Immunology</i> , 2017, 8, 798.	2.2	41
49	Characterization of T and B cell repertoire diversity in patients with RAG deficiency. <i>Science Immunology</i> , 2016, 1, .	5.6	88
50	HSCT for DOCK8 Deficiency - an International Study on 74 Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S103-S104.	2.0	2
51	Plasma and Intracellular Pharmacokinetic (PK) Analysis of Fludarabine in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S253.	2.0	0
52	O-008â€”Aberrant Anti-inflammatory Macrophage Function and Differentiation in Wiskott-Aldrich Syndrome Protein-Deficient Mice and Humans. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S3.	0.9	1
53	Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 852-859.e3.	1.5	48
54	Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up. <i>Blood</i> , 2016, 128, 1306-1308.	0.6	40

#	ARTICLE	IF	CITATIONS
55	Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S101-S102.	2.0	3
56	A novel mutation in the POLE2 gene causing combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 635-638.e1.	1.5	49
57	Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 324-327.e2.	1.5	13
58	Preclinical Development of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1). <i>Blood</i> , 2016, 128, 4705-4705.	0.6	1
59	Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. <i>Blood</i> , 2015, 125, 3886-3895.	0.6	33
60	The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. <i>Haematologica</i> , 2015, 100, 978-988.	1.7	161
61	Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. <i>Journal of Experimental Medicine</i> , 2015, 212, 939-951.	4.2	241
62	A Case of Leaky SCID with Variable Presentation in Two Siblings Identified By Newborn Screening. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB15.	1.5	1
63	DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients. <i>Journal of Clinical Immunology</i> , 2015, 35, 189-198.	2.0	284
64	Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S289-S291.	2.0	2
65	A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 479-482.e1.	1.5	28
66	Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1401-1404.e3.	1.5	25
67	A novel mutation in ICOS presenting as hypogammaglobulinemia with susceptibility to opportunistic pathogens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 794-797.e1.	1.5	26
68	Gene Therapy Using a Self-Inactivating Lentiviral Vector Improves Clinical and Laboratory Manifestations of Wiskott-Aldrich Syndrome. <i>Blood</i> , 2015, 126, 260-260.	0.6	12
69	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 729.	3.8	586
70	Stem cell transplantation for primary immunodeficiency diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 521-526.	1.1	36
71	Retrospective Study of 240 Patients with Severe Combined Immunodeficiency Transplanted from 2000-2009: A Report from the Primary Immune Deficiency Treatment Consortium of North America. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S24-S25.	2.0	1
72	Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 221-223.e7.	1.5	62

#	ARTICLE	IF	CITATIONS
73	Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1092-1098.	1.5	301
74	A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1099-1108.e12.	1.5	132
75	Primary Immune Deficiency Treatment Consortium (PIDTC) report. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 335-347.e11.	1.5	65
76	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009. <i>New England Journal of Medicine</i> , 2014, 371, 434-446.	13.9	594
77	Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 935-943.e15.	1.5	82
78	A Modified $\beta$ -Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. <i>New England Journal of Medicine</i> , 2014, 371, 1407-1417.	13.9	358
79	363 Human Hematopoietic Stem Cells With a Defined Immunodeficiency and Enteropathy Transfer Clinical Phenotype to a Novel Humanized Mouse Strain. <i>Gastroenterology</i> , 2014, 146, S-81.	0.6	2
80	Next Generation Sequencing Reveals Skewing of the T and B Cell Receptor Repertoires in Patients with Wiskott-Aldrich Syndrome. <i>Frontiers in Immunology</i> , 2014, 5, 340.	2.2	40
81	Itm2a, a Target Gene of GATA-3, Plays a Minimal Role in Regulating the Development and Function of T Cells. <i>PLoS ONE</i> , 2014, 9, e96535.	1.1	26
82	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. <i>Journal of Clinical Immunology</i> , 2013, 33, 1156-1164.	2.0	100
83	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1608-1614.	2.0	69
84	Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 656-664.e17.	1.5	140
85	GATA-3 Regulates the Homeostasis and Activation of CD8+ T Cells. <i>Journal of Immunology</i> , 2013, 190, 428-437.	0.4	37
86	First reported case of Omenn syndrome in a patient with reticular dysgenesis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1227-1230.e3.	1.5	32
87	Expanding the spectrum of recombination-activating gene 1 deficiency: A family with early-onset autoimmunity. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 969-971.e2.	1.5	59
88	Gene Therapy Through Autologous Transplantation of Gene-Modified Hematopoietic Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S64-S69.	2.0	23
89	Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1136-1145.	1.5	27
90	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 121, 5113-5123.	0.6	507

#	ARTICLE	IF	CITATIONS
91	P-200â€fHuman Hematopoietic Stem Cells with a Defined Immunodeficiency Transfer Clinical Phenotype to Novel Humanized Mouse Strain. Inflammatory Bowel Diseases, 2013, 19, S105.	0.9	0
92	Stem cell transplantation and immune reconstitution in immunodeficiency. , 2013, , 1007-1019.		0
93	Multicenter Study of â€œoff-the-Shelfâ€Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457.	0.6	2
94	Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia. Journal of Allergy and Clinical Immunology, 2011, 128, 139-146.	1.5	36
95	Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). Biology of Blood and Marrow Transplantation, 2011, 17, S151-S152.	2.0	4
96	A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Molecular Genetics and Metabolism, 2011, 104, 383-389.	0.5	93
97	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood, 2011, 118, 1675-1684.	0.6	296
98	IL-21 is the primary common Î³ chain-binding cytokine required for human B-cell differentiation in vivo. Blood, 2011, 118, 6824-6835.	0.6	132
99	Somatic Gene Therapy for X-Linked Severe Combined Immunodeficiency Using a Self-Inactivating Modified Gammaretroviral Vector Results in An Improved Preclinical Safety Profile and Early Clinical Efficacy in a Human Patient. Blood, 2011, 118, 164-164.	0.6	3
100	Guidelines for implementation of populationâ€based newborn screening for severe combined immunodeficiency. Journal of Inherited Metabolic Disease, 2010, 33, 273-281.	1.7	60
101	Rac GTPases in Human Diseases. Disease Markers, 2010, 29, 177-187.	0.6	71
102	High-Throughput Multiplexed T-Cellâ€Receptor Excision Circle Quantitative PCR Assay with Internal Controls for Detection of Severe Combined Immunodeficiency in Population-Based Newborn Screening. Clinical Chemistry, 2010, 56, 1466-1474.	1.5	74
103	p53<sup>+</sup>/mdm2<sup>â€™</sup> Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma in Young Children: An Early Expression of Li-Fraumeni Syndrome. Pediatric and Developmental Pathology, 2010, 13, 218-224.	0.5	28
104	Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: Advances in Biology and Future Directions for Treatment. Immunology and Allergy Clinics of North America, 2010, 30, 179-194.	0.7	50
105	Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. Journal of Allergy and Clinical Immunology, 2010, 126, 1304-1305.e3.	1.5	61
106	Identification of an infant with severe combined immunodeficiency by newborn screening. Journal of Allergy and Clinical Immunology, 2010, 126, 1073-1074.	1.5	48
107	Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3546-3551.	3.3	141
108	Rac GTPases in human diseases. Disease Markers, 2010, 29, 177-87.	0.6	33



#	ARTICLE	IF	CITATIONS
109	CDK Inhibitor p18INK4c Is a Downstream Target of GATA3 and Restrains Mammary Luminal Progenitor Cell Proliferation and Tumorigenesis. <i>Cancer Cell</i> , 2009, 15, 389-401.	7.7	82
110	Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: case report and review of outcomes. <i>Immunologic Research</i> , 2009, 44, 89-98.	1.3	48
111	GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. <i>Nature Reviews Immunology</i> , 2009, 9, 125-135.	10.6	344
112	Novel presentation of Omenn syndrome in association with aniridia. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 966-969.	1.5	10
113	GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer Model. <i>Cancer Cell</i> , 2008, 13, 141-152.	7.7	314
114	Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor- $\hat{\rho}$ B essential modulator deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 1113-1118.e1.	1.5	45
115	Distinct Structural Requirements of GATA-3 for the Regulation of Thymocyte and Th2 Cell Differentiation. <i>Journal of Immunology</i> , 2008, 180, 1050-1059.	0.4	11
116	GATA-3 - not just for Th2 cells anymore. <i>Cellular and Molecular Immunology</i> , 2007, 4, 15-29.	4.8	71
117	Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3. <i>Journal of Cell Biology</i> , 2006, 175, 661-670.	2.3	80
118	GATA-3 Regulates the Development and Function of Invariant NKT Cells. <i>Journal of Immunology</i> , 2006, 177, 6650-6659.	0.4	108
119	GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1993-1998.	3.3	299
120	Critical Roles for Transcription Factor GATA-3 in Thymocyte Development. <i>Immunity</i> , 2003, 19, 863-875.	6.6	277
121	c-Rel delivers a one-two punch in Th1 cell differentiation. <i>Journal of Clinical Investigation</i> , 2002, 110, 741-742.	3.9	8
122	c-Rel delivers a one-two punch in Th1 cell differentiation. <i>Journal of Clinical Investigation</i> , 2002, 110, 741-742.	3.9	3
123	Cross-linking CD28 leads to activation of 70-kDa S6 kinase. <i>European Journal of Immunology</i> , 1994, 24, 2364-2368.	1.6	34
124	The current status of treatment for anorexia nervosa and bulimia nervosa. <i>International Journal of Eating Disorders</i> , 1992, 12, 215-220.	2.1	34